source
- FDA approves Regeneron's first siRNA therapy for generalized myasthenia gravisThe FDA has granted approval for Regeneron's siRNA drug Livsayis (cemdisiran) for adult patients with generalized myasthenia gravis who are positive for anti‑acetylcholine receptor antibodies. Thi…
- FDA approves treatments for four rare diseases; Pfizer inks $2.6 billion China licensing deal for CAR‑T therapyThe U.S. Food and Drug Administration has granted approval for drugs targeting four distinct rare diseases, expanding therapeutic options for patients with limited treatment choices. In a separate…